IL247624A0 - Intentional healing - Google Patents

Intentional healing

Info

Publication number
IL247624A0
IL247624A0 IL247624A IL24762416A IL247624A0 IL 247624 A0 IL247624 A0 IL 247624A0 IL 247624 A IL247624 A IL 247624A IL 24762416 A IL24762416 A IL 24762416A IL 247624 A0 IL247624 A0 IL 247624A0
Authority
IL
Israel
Prior art keywords
targeted therapeutics
therapeutics
targeted
Prior art date
Application number
IL247624A
Other languages
English (en)
Hebrew (he)
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of IL247624A0 publication Critical patent/IL247624A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL247624A 2014-03-03 2016-09-04 Intentional healing IL247624A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461947108P 2014-03-03 2014-03-03
PCT/US2015/018442 WO2015134464A2 (en) 2014-03-03 2015-03-03 Targeted therapeutics

Publications (1)

Publication Number Publication Date
IL247624A0 true IL247624A0 (en) 2016-11-30

Family

ID=54055980

Family Applications (1)

Application Number Title Priority Date Filing Date
IL247624A IL247624A0 (en) 2014-03-03 2016-09-04 Intentional healing

Country Status (10)

Country Link
US (2) US10232049B2 (enExample)
EP (1) EP3129064B1 (enExample)
JP (2) JP6576942B6 (enExample)
KR (1) KR20160126078A (enExample)
CN (1) CN106456795A (enExample)
AU (1) AU2015224576A1 (enExample)
CA (1) CA2941618A1 (enExample)
IL (1) IL247624A0 (enExample)
MA (1) MA39481A (enExample)
WO (1) WO2015134464A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3131586A4 (en) * 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
LT3660004T (lt) * 2016-10-11 2023-06-12 Arvinas Operations, Inc. Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai
JP2020524156A (ja) * 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬を含む併用療法
JP2020524154A (ja) * 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬
US20200230247A1 (en) * 2017-06-20 2020-07-23 Tarveda Therapeutics, Inc. Combination therapies comprising targeted therapeutics
CN109512821B (zh) * 2017-09-18 2021-06-08 无锡富泽药业有限公司 一种克唑替尼与17-aag复合聚合物纳米胶束注射剂、其制备方法及其应用
AU2018386218A1 (en) * 2017-12-14 2020-07-02 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
SG11202011135WA (en) 2018-05-14 2020-12-30 Nuvation Bio Inc Anti-cancer nuclear hormone receptor-targeting compounds
EP3801506A4 (en) * 2018-06-01 2022-08-10 Tva (Abc), Llc POLYTHERAPY
CN109575044A (zh) * 2018-12-21 2019-04-05 西安交通大学 2-（喜树碱-10-氧基）乙酰胺类化合物和应用
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
WO2020210451A1 (en) * 2019-04-10 2020-10-15 Dana-Farber Cancer Institute, Inc. Degraders of fibroblast growth factor receptor 2 (fgfr2)
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN110003181B (zh) * 2019-05-22 2020-08-28 北京凯恩梅格医药科技有限公司 一种基于克唑替尼结构的c-Met/HDAC双靶点抑制剂及其合成方法与应用
EP4126833B1 (en) * 2020-03-23 2026-05-20 Helmholtz Zentrum Infektionsforschung Gmbh N-PHENYL-3-MERCAPTOPROPANAMIDES DERIVATIVES AS METALLO-BETA-LACTAMASES INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS
CN111499623B (zh) * 2020-04-01 2022-07-08 南京缘聚医药科技有限公司 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途
EP4146642A1 (en) 2020-05-09 2023-03-15 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
CA3207282A1 (en) 2021-02-15 2022-08-18 Matthew J. Sharp Abiraterone prodrugs
KR20230160299A (ko) 2021-03-23 2023-11-23 누베이션 바이오 인크. 항암 핵 호르몬 수용체 표적화 화합물
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114933584B (zh) * 2021-08-09 2022-12-27 上海贵之言医药科技有限公司 一种二氢-2h-异吲哚酯类化合物
CN116354933B (zh) * 2021-12-27 2025-06-20 青岛普泰科生物医药科技有限公司 作为雄激素受体调节剂的杂环化合物及其应用
CN115650975B (zh) * 2022-08-23 2024-07-02 四川大学华西医院 一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用
WO2024197429A1 (zh) * 2023-03-24 2024-10-03 青岛普泰科生物医药科技有限公司 作为雄激素受体调节剂的杂环化合物及其应用
CN117720514A (zh) * 2023-03-31 2024-03-19 福建医科大学 一种基于分子胶原理降解Hsp90的化合物、其制备方法及其在治疗肿瘤中的应用
CN121487739A (zh) * 2023-03-31 2026-02-06 珃诺生物医药科技(杭州)有限公司 用于靶向蛋白降解的方法和组合物
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025199665A1 (en) * 2024-03-23 2025-10-02 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
EP1337275A4 (en) 2000-11-02 2007-05-09 Sloan Kettering Inst Cancer METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
JP2005520795A (ja) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
US6759416B2 (en) 2002-08-06 2004-07-06 Panorama Research, Inc. Anticancer conjugates of camptothecin and unsaturated fatty acids
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
EP1581261A4 (en) 2002-12-12 2009-10-21 Conforma Therapeutics Corp Cytotoxins and agents for diagnostic imaging with HSP90 ligands
WO2005095347A1 (en) 2004-03-26 2005-10-13 Van Andel Research Institute Geldanamycin and derivatives inhibit cancer invasion and identify novel targets
EP2298748B1 (en) 2004-11-18 2016-07-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
WO2007053792A2 (en) 2005-11-05 2007-05-10 Amplyx Pharmaceuticals, Inc. Improving the pharmacokinetics of protease inhibitors and other drugs
US8293726B2 (en) 2005-12-02 2012-10-23 Vianova Labs, Inc. Treatment of cancer and other diseases
GB0526615D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
TWI490212B (zh) 2006-05-25 2015-07-01 Synta Pharmaceuticals Corp 調節ｈｓｐ９０活性之三唑化合物
JP5599610B2 (ja) 2006-06-30 2014-10-01 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０の阻害による神経変性疾患の処置
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
WO2008057246A2 (en) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
CA2680161A1 (en) 2007-03-05 2008-09-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
EP2180880A2 (en) 2007-07-09 2010-05-05 Glen S. Kwon Micelle encapsulation of therapeutic agents
CN101854955B (zh) 2007-09-10 2012-07-18 马萨诸塞大学 靶向线粒体的抗肿瘤剂
US20110270151A1 (en) 2008-09-08 2011-11-03 The Methodist Hospital Research Institute Image-guided energy deposition for targeted drug delivery
WO2011116181A1 (en) 2010-03-17 2011-09-22 Caris Life Sciences, Inc. Theranostic and diagnostic methods using sparc and hsp90
US8546425B2 (en) 2008-09-17 2013-10-01 Purdue Research Foundation Folate receptor binding conjugates of antifolates
US20110217241A1 (en) 2008-11-14 2011-09-08 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging
PE20120630A1 (es) * 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
US20110268722A1 (en) 2010-04-22 2011-11-03 Siegelin Markus D Combination therapies with mitochondrial-targeted anti-tumor agents
KR20140021520A (ko) 2010-10-22 2014-02-20 위니베르시떼 드 스트라스부르 Hsp90 관련 질환의 치료에 유용한 포코옥심 컨쥬게이트
EP2663305A1 (en) * 2011-01-11 2013-11-20 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
EP2766723A4 (en) * 2011-10-12 2015-06-10 Univ North Carolina MULTIPLEXED KINASE HEMMER BEADS AND THEIR USE
CA2855368A1 (en) * 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CA2865021C (en) * 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP3925627A1 (en) 2012-05-15 2021-12-22 Concortis Biosystems, Corp Drug-conjugates and uses thereof
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
EP3035938B1 (en) 2013-09-10 2020-08-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
EP3057610B1 (en) 2013-10-15 2021-09-22 Sorrento Therapeutics, Inc. Drug-conjugates with a targeting molecule and two different drugs
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP4062917B1 (en) 2013-12-20 2025-12-03 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
WO2015116774A1 (en) 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Targeted therapeutics

Also Published As

Publication number Publication date
JP6576942B2 (ja) 2019-09-18
CN106456795A (zh) 2017-02-22
WO2015134464A3 (en) 2015-10-29
US20190060478A1 (en) 2019-02-28
US10675360B2 (en) 2020-06-09
WO2015134464A2 (en) 2015-09-11
US20170049899A1 (en) 2017-02-23
EP3129064A2 (en) 2017-02-15
KR20160126078A (ko) 2016-11-01
JP6576942B6 (ja) 2019-11-27
JP2017507150A (ja) 2017-03-16
AU2015224576A1 (en) 2016-09-22
EP3129064A4 (en) 2017-10-25
MA39481A (fr) 2015-09-11
CA2941618A1 (en) 2015-09-11
EP3129064B1 (en) 2020-01-01
JP2019196406A (ja) 2019-11-14
US10232049B2 (en) 2019-03-19

Similar Documents

Publication Publication Date Title
IL283100A (en) Glyco-directed therapy
DK3237446T3 (en) Anti-PD-1-antistoffer
DK3236972T3 (en) Antivirale N4-hydroxycytidin-derivativer
DK3373003T3 (en) Urinteststrimmel
EP3129064A4 (en) Targeted therapeutics
AU361515S (en) Dishrack
AU362944S (en) Lapboard
EP3131586A4 (en) Targeted therapeutics
EP3099332A4 (en) Targeted therapeutics
DK3191586T3 (en) Cellobiosephosphorylase
PL3237349T3 (pl) Ulepszony biologiczny środek wiążący
DK3178931T3 (en) Anti-orai1-antistof
IL246956A0 (en) targeted therapies
DK3002465T3 (en) Hydrauliksystem
DK3194944T3 (en) Tomografiapparat
GB201419650D0 (en) Modified heterocyclase
GB201419494D0 (en) Variations
DK3145380T3 (en) Toiletventilationssystem
GB2559497B (en) Functional wall-tie
DK3234061T3 (en) Nano-inhibitorer
AU5592P (en) Lanmichigan Mandevilla boliviensis x sanderi
AU5598P (en) Lanidaho Mandevilla sanderi
AU5593P (en) Lanmissouri Mandevilla sanderi
AU5594P (en) Lanoregon Mandevilla sanderi
AU5585P (en) Lanutah Mandevilla sanderi